Company intelligence / Profile preview

Fidelis Animal Health

North Brunswick, New Jersey, United Statesfidelisah.com ↗

Ownership: Private
Development stage: Other

Overview

Fidelis Animal Health has commercialized Ethiqa XR, an FDA-indexed extended-release buprenorphine injection for post-procedural pain control in a wide range of laboratory animals. The product delivers up to 72 hours of analgesia with a single subcutaneous injection and is used at over 200 institutions nationwide. The company is expanding indications and developing additional products using its proprietary drug delivery platform

Therapeutic areas: Other
Modalities: Small moleculeExtended-release injectable formulationLipid-based drug delivery system (Fidelipid LAI)
Industry: Veterinary

Partnerships

Not specifically disclosed; may include academic research institutions as end users.

Beyond the preview

Go deeper on Fidelis Animal Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fidelis Animal Health.

Explore the full profile